Mike Partridge Ph.D., CPhys, MInstP
Dr Mike Partridge
|Tel||+44 (0)1865 857044 / +44 (0)1865 225842 (PA)|
|Contact address||Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ|
|Department||Department of Oncology|
Personalizing radiotherapy using functional imaging.
Translation of radiotherapy from the laboratory to the clinical setting requires close collaboration with clinical teams. The ultimate goal of my team is to harness technical advances in both medical imaging and radiation delivery to provide improved radiotherapy for individual patients. Recent advances have greatly improved the accuracy and reproducibility of radiotherapy delivery, with improved targeting of radiation to the three-dimensional structure of tumours whilst sparing normal tissue; in parallel with this has been an improved understanding of the biology and behaviour of tumours in real patients. The focus of tailored radiotherapy is to better deliver radiation to patients based on their own biology. One avenue of research involves monitoring response to treatment so that it can be modified in real time according to patient response, using medical imaging techniques to advance biologically-adaptive radiotherapy.
Imaging data from trials at Oxford are being assessed to determine whether response to treatment (radiotherapy and chemotherapy) can be predicted from functional imaging, and to determine whether escalating to more aggressive (potentially more effective) treatment in patients failing to show early response is feasible. This work will be carried out in close collaboration with radiation oncologists and clinicians. One example is the evaluation of [18F]-fluoromisonidazole (FMISO) as a tracer of hypoxia in rectal cancer (the RHYTHM trial). In one cohort of patients, maps of FMISO uptake from images acquired immediately prior to surgery will be compared to histopathology as the "gold standard" for validating FMISO as a marker of hypoxia in rectal cancer. Using these data, we will also study the relationship between heterogeneity in the microscopic distribution of tumour hypoxia and the macroscopic imaging. In the parallel cohort, FMISO images taken at baseline will be compared to those acquired after 2 weeks of radiotherapy to see whether early prediction of response to therapy is possible. Strategies for intensification of treatment for non-responding patients, by selectively targeting residual hypoxic volumes will then be developed and tested.
The insight gained from this and similar studies will provide tools and expertise applicable potentially to any imaging biomarker of response and drug treatment that alters radiosensitivity to radiotherapy.
Dr Mike Partridge is a Senior Group Leader at the CRUK/MRC Oxford Institute for Radiation Oncology within the University of Oxford’s Department of Oncology. He has recently established a new team in physics and imaging research in functional-image-guided radiation therapy and high precision radiation therapy methods such as intensity-modulated radiation therapy (IMRT), critical for driving translational research and enabling clinical trials in this area. Dr Partridge has a wealth of experience in the field of radiotherapy and prior to joining Oxford in 2012, he spent 13 years at the Institute of Cancer Research and Royal Marsden NHS Foundation Trust where he helped establish the clinical positron emission tomography / computerised tomography (PET/CT) service within the Royal Marsden and set up a new team investigating the application of functional imaging to radiotherapy planning.
Dr Partridge is a member of the Academic Advisory Group of the Institute of Physics and Engineering in Medicine, a member of the Editorial Board of the British Journal of Radiology and the Australasian Physical Sciences and Engineering in Medicine journal and regularly serves as a referee and associate editor for a range of international journals in medical physics and radiation oncology. He gained an MA in Natural Sciences from the University of Cambridge, a PhD in Imaging from Cranfield University and studies as a postdoctoral research fellow at the Institute of Cancer Research in London and the German Cancer Research Centre (DKFZ) in Heidelberg, Germany. He is a UK state Registered Clinical Scientist and has authored or co-authored over 220 publications on a wide range of topics in radiotherapy and imaging.
Warren S, Partridge M, Fokas E, Eccles CE, Brunner TB (2013) 'Use of radiobiological endpoints to compare treatment planning techniques for pancreatic cancer' Acta Oncologica, in press
Powell, C., Schmidt, M., Borri, M., Koh, D-M., Partridge, M., Riddell, A., Cook, G., Bhide, SA., Nutting, CM., Harrington, KJ., Newbold, KL. (2002) ‘Changes in functional imaging parameters following induction chemotherapy have important implications for individualised patient-based treatment regimens for advanced head and neck cancer’ Radiotherapy & Oncology
Partridge M, Powell C, Koopman M, Vidan LH and Newbold K, 'Technical Note: 9-month Repositioning accuracy for functional response assessment in head and neck chemo-radiotherapy' the British Journal of Radiology, 85 1576-1580 (2012)
Partridge, M., Ramos, M., Sararo, A., & Brada, M. (2011) ‘Dose escalation escalation for non-small cell lung cancer: Analysis and modelling of the literature’ Radiotherapy & Oncology 99 6–11
Buettner, F., Gulliford, SL., Webb, S., & Partridge, M. (2011) ‘Modeling late rectal toxicities based on a parameterized representation of the 3D dose distribution’, Phys Med Biol 56 2103–2118
Guckenberger, M., Richter, A., Wilbert, J., Flentje, M., & Partridge, M. (2011) ‘Adaptive radiotherapy for locally advanced non-small cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control’ IJ Radiation Oncology Biol Phys 81 e275–e282
Brock, J., Bedford, J., Partridge, M., McDonald, F., Ashley, S., McNair, H., & Brada, M. (2012) ‘Optimizing Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer with Volumetric Intensity Modulated Arc Therapy – a Planning Study’ Clinical Oncology 24 68–75
Partridge, M., Yamamoto, T., Grau, C., Høyer, M., & Muren, LP. (2010) ‘Imaging of normal lung, liver and parotid gland function for radiotherapy’ Acta Oncologica 49 997–1011
Perrin, R., Evans, PM., Webb, S., & Partridge, M. (2010) ‘The use of PET images for radiotherapy treatment planning: an error analysis using radiobiological endpoints’ Med Phys 37 516–531
Partridge, M., Tree, A., Brock, J., McNair, H., Panakis, N., & Brada, M. (2009) ‘Improvement in tumour control probability with active breathing control and dose escalation: a modelling study’ Radiother Oncol 91 325–329
South, C., Evans, P., & Partridge, M. (2009) ‘Dose prescription complexity versus tumour control probability in biologically conformal radiotherapy’ Med Phys 36 4379–4388
Partridge, M. (2008) ‘A radiation damage-repair model for normal tissues’ Phys. Med. Biol. 53 3595–3608
Newbold, K., Partridge, M., Cook, G., Sharma, B., Rhys-Evans, PH., Harrington, KJ., Nutting, CM. (2008) ‘Evaluation Of The Role Of 18FDG-PET/CT In Radiotherapy Target Definition In Patients With Head And Neck Cancer’, Acta Oncologica 47 1229–1236
Lavrenkov, K., Christian, JA., Partridge, M., Niotsiokou, E., Cook, G., Parker, M., Bedford, JL., & Brada, M. (2007) ‘A potential to reduce pulmonary toxicity: the use of IMRT for function lung avoidance in radiotherapy of non-small-cell lung cancer’ Radiotherapy & Oncology 83 156–162